Symbols / VSTM
VSTM Chart
About
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 444.39M |
| Enterprise Value | 332.39M | Income | -241.11M | Sales | 13.38M |
| Book/sh | -0.23 | Cash/sh | 2.06 | Dividend Yield | — |
| Payout | 0.00% | Employees | 78 | IPO | — |
| P/E | — | Forward P/E | -3.59 | PEG | — |
| P/S | 33.22 | P/B | -25.32 | P/C | — |
| EV/EBITDA | -2.08 | EV/Sales | 24.84 | Quick Ratio | 2.42 |
| Current Ratio | 2.58 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -4.42 | EPS next Y | -1.64 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-04 | ROA | -66.06% |
| ROE | -28.89% | ROIC | — | Gross Margin | 85.14% |
| Oper. Margin | -3.62% | Profit Margin | 0.00% | Shs Outstand | 75.32M |
| Shs Float | 55.72M | Short Float | 21.92% | Short Ratio | 8.31 |
| Short Interest | — | 52W High | 11.25 | 52W Low | 4.01 |
| Beta | 0.39 | Avg Volume | 1.93M | Volume | 996.02K |
| Target Price | $17.00 | Recom | Strong_buy | Prev Close | $5.70 |
| Price | $5.90 | Change | 3.51% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$17.00
Mean price target
2. Current target
$5.90
Latest analyst target
3. DCF / Fair value
$-19.26
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.90
Low
$14.00
High
$20.00
Mean
$17.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-09 | reit | BTIG | Buy → Buy | $20 |
| 2025-08-08 | main | RBC Capital | Outperform → Outperform | $13 |
| 2025-06-25 | main | RBC Capital | Outperform → Outperform | $12 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-04-10 | init | Jefferies | — → Buy | $15 |
| 2025-04-09 | main | Mizuho | Outperform → Outperform | $8 |
| 2025-03-24 | main | Guggenheim | Buy → Buy | $14 |
| 2025-03-24 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-21 | main | RBC Capital | Outperform → Outperform | $14 |
| 2025-01-31 | main | B. Riley Securities | Buy → Buy | $9 |
| 2025-01-24 | reit | Guggenheim | Buy → Buy | — |
| 2025-01-07 | main | RBC Capital | Outperform → Outperform | $16 |
| 2024-12-19 | main | Mizuho | Outperform → Outperform | $9 |
| 2024-12-19 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-13 | main | Truist Securities | Buy → Buy | $15 |
| 2024-08-12 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-09 | main | RBC Capital | Outperform → Outperform | $13 |
| 2024-07-24 | main | B. Riley Securities | Buy → Buy | $7 |
| 2024-07-08 | main | Truist Securities | Buy → Buy | $18 |
| 2024-05-29 | main | Alliance Global Partners | Buy → Buy | $20 |
- What Makes Verastem (VSTM) a New Buy Stock - Yahoo Finance ue, 17 Feb 2026 17
- Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Business Wire Wed, 18 Feb 2026 12
- $VSTM stock is down 16% today. Here's what we see in our data. - Quiver Quantitative Mon, 20 Oct 2025 07
- Verastem, Inc. (VSTM) Stock Analysis: Nearly 100% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews Fri, 24 Oct 2025 07
- B.Riley reiterates Buy rating on Verastem stock, maintains $16 target - Investing.com Nigeria Wed, 04 Feb 2026 08
- Verastem Oncology drops despite Q3 double beat (VSTM:NASDAQ) - Seeking Alpha ue, 04 Nov 2025 08
- Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results - Finviz hu, 05 Feb 2026 08
- Verastem, Inc. (VSTM) Stock Analysis: A 188% Upside Potential In Biotech Innovation - DirectorsTalk Interviews Fri, 25 Jul 2025 07
- Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire Wed, 04 Feb 2026 08
- Verastem, Inc. (NASDAQ:VSTM) is favoured by institutional owners who hold 60% of the company - Yahoo Finance Mon, 15 Dec 2025 08
- Insider Sale: President and CEO of $VSTM Sells 10,321 Shares - Quiver Quantitative Wed, 14 Jan 2026 08
- Verastem Oncology Announces Proposed Public Offering of Common Stock - Business Wire hu, 13 Nov 2025 08
- Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline - Yahoo Finance hu, 31 Jul 2025 07
- Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet - Yahoo Finance Mon, 20 Oct 2025 07
- VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval - Nasdaq Wed, 28 May 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 970 | 6489 | — | Sale at price 6.69 per share. | PATERSON DANIEL W | Chief Executive Officer | — | 2026-02-04 00:00:00 | D |
| 1 | 213785 | — | — | Stock Award(Grant) at price 0.00 per share. | PATERSON DANIEL W | Chief Executive Officer | — | 2026-01-21 00:00:00 | D |
| 2 | 16665 | — | — | Stock Award(Grant) at price 0.00 per share. | CALKINS DANIEL | Chief Financial Officer | — | 2026-01-21 00:00:00 | D |
| 3 | 10321 | 73898 | — | Sale at price 7.16 per share. | PATERSON DANIEL W | Chief Executive Officer | — | 2026-01-12 00:00:00 | D |
| 4 | 5039 | 36079 | — | Sale at price 7.16 per share. | CALKINS DANIEL | Chief Financial Officer | — | 2026-01-12 00:00:00 | D |
| 5 | 80 | 629 | — | Sale at price 7.86 per share. | CALKINS DANIEL | Chief Financial Officer | — | 2025-12-24 00:00:00 | D |
| 6 | 283 | 2587 | — | Sale at price 9.14 per share. | GAGNON ROBERT E | Director | — | 2025-12-16 00:00:00 | D |
| 7 | 393 | 3592 | — | Sale at price 9.14 per share. | PATERSON DANIEL W | Chief Executive Officer | — | 2025-12-16 00:00:00 | D |
| 8 | 592 | 5411 | — | Sale at price 9.14 per share. | STUGLIK BRIAN M | Director | — | 2025-12-16 00:00:00 | D |
| 9 | 4000 | 40140 | — | Sale at price 10.00 - 10.07 per share. | PATERSON DANIEL W | Chief Executive Officer | — | 2025-12-11 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -4.02M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -106.72M | -83.17M | -71.56M | -61.16M |
| TotalUnusualItems | -19.15M | 0.00 | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | -19.15M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -130.64M | -87.37M | -73.81M | -71.20M |
| ReconciledDepreciation | 26.00K | 62.00K | 118.00K | 72.00K |
| ReconciledCostOfRevenue | 0.00 | 0.00 | ||
| EBITDA | -125.86M | -83.17M | -71.56M | -61.16M |
| EBIT | -125.89M | -83.23M | -71.67M | -61.23M |
| NetInterestIncome | -413.00K | 2.08M | -922.00K | -9.79M |
| InterestExpense | 4.56M | 4.14M | 2.14M | 9.97M |
| InterestIncome | 4.15M | 6.21M | 1.22M | 181.00K |
| NormalizedIncome | -115.51M | -87.37M | -73.81M | -71.20M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -130.64M | -87.37M | -73.81M | -71.20M |
| TotalExpenses | 124.96M | 92.08M | 75.53M | 63.46M |
| TotalOperatingIncomeAsReported | -114.96M | -92.08M | -72.94M | -61.41M |
| DilutedAverageShares | 35.71M | 22.05M | 16.14M | 14.53M |
| BasicAverageShares | 35.71M | 22.05M | 16.14M | 14.53M |
| DilutedEPS | -3.66 | -3.96 | -4.57 | -4.92 |
| BasicEPS | -3.66 | -3.96 | -4.57 | -4.92 |
| DilutedNIAvailtoComStockholders | -130.64M | -87.37M | -73.81M | -71.20M |
| NetIncomeCommonStockholders | -130.64M | -87.37M | -73.81M | -71.20M |
| NetIncome | -130.64M | -87.37M | -73.81M | -71.20M |
| NetIncomeIncludingNoncontrollingInterests | -130.64M | -87.37M | -73.81M | -71.20M |
| NetIncomeContinuousOperations | -130.64M | -87.37M | -73.81M | -71.20M |
| TaxProvision | 185.00K | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -130.45M | -87.37M | -73.81M | -71.20M |
| OtherIncomeExpense | -15.08M | 2.64M | 47.00K | |
| OtherNonOperatingIncomeExpenses | 4.07M | 2.64M | 47.00K | |
| SpecialIncomeCharges | 0.00 | 0.00 | ||
| GainOnSaleOfSecurity | -19.15M | |||
| NetNonOperatingInterestIncomeExpense | -413.00K | 2.08M | -922.00K | -9.79M |
| InterestExpenseNonOperating | 4.56M | 4.14M | 2.14M | 9.97M |
| InterestIncomeNonOperating | 4.15M | 6.21M | 1.22M | 181.00K |
| OperatingIncome | -114.96M | -92.08M | -72.94M | -61.41M |
| OperatingExpense | 124.96M | 92.08M | 75.53M | 63.46M |
| ResearchAndDevelopment | 81.33M | 61.36M | 50.56M | 39.35M |
| SellingGeneralAndAdministration | 43.62M | 30.73M | 24.98M | 24.11M |
| GrossProfit | 2.60M | 2.05M | ||
| CostOfRevenue | 0.00 | 0.00 | ||
| TotalRevenue | 10.00M | 0.00 | 2.60M | 2.05M |
| OperatingRevenue | 10.00M | 0.00 | 2.60M | 1.45M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 44.78M | 25.28M | 16.71M | 15.44M |
| ShareIssued | 44.78M | 25.28M | 16.71M | 15.44M |
| TotalDebt | 42.25M | 41.56M | 27.07M | 3.18M |
| TangibleBookValue | -28.89M | 57.37M | 47.39M | 87.56M |
| InvestedCapital | 11.83M | 97.46M | 72.19M | 87.81M |
| WorkingCapital | 63.99M | 117.30M | 71.21M | 87.15M |
| NetTangibleAssets | -28.89M | 57.37M | 47.39M | 87.56M |
| CapitalLeaseObligations | 1.53M | 1.47M | 2.26M | 2.93M |
| CommonStockEquity | -28.89M | 57.37M | 47.39M | 87.56M |
| TotalCapitalization | 11.83M | 97.46M | 71.92M | 87.81M |
| TotalEquityGrossMinorityInterest | -28.89M | 57.37M | 47.39M | 87.56M |
| StockholdersEquity | -28.89M | 57.37M | 47.39M | 87.56M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 13.00K | 0.00 | 34.00K |
| OtherEquityAdjustments | 13.00K | 34.00K | ||
| RetainedEarnings | -955.53M | -824.89M | -737.52M | -663.71M |
| AdditionalPaidInCapital | 926.63M | 882.25M | 784.91M | 751.22M |
| CapitalStock | 4.00K | 3.00K | 2.00K | 19.00K |
| CommonStock | 4.00K | 3.00K | 2.00K | 19.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 130.43M | 92.34M | 47.66M | 21.10M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 99.46M | 65.96M | 26.00M | 2.51M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 25.35M | 0.00 | |
| DerivativeProductLiabilities | 58.20M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 41.26M | 40.62M | 26.00M | 2.51M |
| LongTermCapitalLeaseObligation | 535.00K | 530.00K | 1.47M | 2.26M |
| LongTermDebt | 40.72M | 40.09M | 24.53M | 249.00K |
| CurrentLiabilities | 30.97M | 26.38M | 21.66M | 18.59M |
| CurrentDeferredLiabilities | 0.00 | 327.00K | 710.00K | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 995.00K | 941.00K | 1.07M | 667.00K |
| CurrentCapitalLeaseObligation | 995.00K | 941.00K | 794.00K | 667.00K |
| CurrentDebt | 275.00K | |||
| OtherCurrentBorrowings | 275.00K | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.25M | 4.80M | 3.84M | 3.89M |
| PayablesAndAccruedExpenses | 23.73M | 20.32M | 16.04M | 14.03M |
| CurrentAccruedExpenses | 19.71M | 13.13M | 11.14M | 11.73M |
| InterestPayable | 316.00K | 316.00K | 192.00K | 3.00K |
| Payables | 4.03M | 7.18M | 4.90M | 2.30M |
| AccountsPayable | 4.03M | 7.18M | 4.90M | 2.30M |
| TotalAssets | 101.54M | 149.72M | 95.05M | 108.66M |
| TotalNonCurrentAssets | 6.58M | 6.04M | 2.18M | 2.92M |
| OtherNonCurrentAssets | 5.14M | 4.83M | 299.00K | 410.00K |
| InvestmentsAndAdvances | 0.00 | |||
| NetPPE | 1.44M | 1.21M | 1.88M | 2.51M |
| AccumulatedDepreciation | -1.62M | -1.59M | -1.53M | -1.68M |
| GrossPPE | 3.06M | 2.80M | 3.41M | 4.19M |
| Leases | 146.00K | 146.00K | 146.00K | 146.00K |
| OtherProperties | 1.41M | 1.18M | 1.79M | 2.30M |
| MachineryFurnitureEquipment | 1.50M | 1.48M | 1.48M | 1.74M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 94.96M | 143.68M | 92.87M | 105.74M |
| OtherCurrentAssets | 5.94M | 6.55M | 4.95M | 4.97M |
| PrepaidAssets | 4.95M | 4.97M | ||
| Receivables | 200.00K | 0.00 | 31.00K | 516.00K |
| AccountsReceivable | 200.00K | 0.00 | 31.00K | 516.00K |
| CashCashEquivalentsAndShortTermInvestments | 88.82M | 137.13M | 87.89M | 100.26M |
| OtherShortTermInvestments | 0.00 | 59.22M | 12.96M | 79.00M |
| CashAndCashEquivalents | 88.82M | 77.91M | 74.93M | 21.25M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -104.80M | -86.46M | -63.67M | -53.70M |
| RepurchaseOfCapitalStock | -925.00K | |||
| RepaymentOfDebt | -150.00K | -300.00K | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 14.92M | 24.15M | 0.00 |
| IssuanceOfCapitalStock | 14.22M | 119.52M | 27.35M | 6.72M |
| CapitalExpenditure | -28.00K | -196.00K | ||
| InterestPaidSupplementalData | 3.77M | 3.36M | 1.54M | 1.01M |
| EndCashPosition | 89.06M | 79.08M | 75.79M | 21.49M |
| BeginningCashPosition | 79.08M | 75.79M | 21.49M | 68.02M |
| ChangesInCash | 9.98M | 3.29M | 54.30M | -46.53M |
| FinancingCashFlow | 54.78M | 134.19M | 51.78M | 6.88M |
| CashFlowFromContinuingFinancingActivities | 54.78M | 134.19M | 51.78M | 6.88M |
| NetOtherFinancingCharges | -925.00K | |||
| InterestPaidCFF | 0.00 | 0.00 | ||
| ProceedsFromStockOptionExercised | 40.71M | 57.00K | 282.00K | 1.09M |
| CashDividendsPaid | 0.00 | 0.00 | ||
| NetPreferredStockIssuance | 0.00 | 28.10M | 0.00 | 0.00 |
| PreferredStockIssuance | 0.00 | 28.10M | 0.00 | 0.00 |
| NetCommonStockIssuance | 14.22M | 91.42M | 27.35M | 6.72M |
| CommonStockPayments | -925.00K | |||
| CommonStockIssuance | 14.22M | 91.42M | 27.35M | 6.72M |
| NetIssuancePaymentsOfDebt | -150.00K | 14.62M | 24.15M | 0.00 |
| NetLongTermDebtIssuance | -150.00K | 14.62M | 24.15M | 0.00 |
| LongTermDebtPayments | -150.00K | -300.00K | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 14.92M | 24.15M | 0.00 |
| InvestingCashFlow | 59.97M | -44.45M | 66.19M | 87.00K |
| CashFlowFromContinuingInvestingActivities | 59.97M | -44.45M | 66.19M | 87.00K |
| NetInvestmentPurchaseAndSale | 60.00M | -44.45M | 66.19M | 283.00K |
| SaleOfInvestment | 60.00M | 52.00M | 84.00M | 86.72M |
| PurchaseOfInvestment | 0.00 | -96.45M | -17.82M | -86.44M |
| NetPPEPurchaseAndSale | -28.00K | 0.00 | 0.00 | -196.00K |
| PurchaseOfPPE | -28.00K | 0.00 | 0.00 | -196.00K |
| OperatingCashFlow | -104.77M | -86.46M | -63.67M | -53.50M |
| CashFlowFromContinuingOperatingActivities | -104.77M | -86.46M | -63.67M | -53.50M |
| ChangeInWorkingCapital | 3.72M | -957.00K | 3.90M | 584.00K |
| ChangeInOtherWorkingCapital | -327.00K | -383.00K | 710.00K | |
| ChangeInOtherCurrentLiabilities | 0.00 | 0.00 | ||
| ChangeInOtherCurrentAssets | 0.00 | 0.00 | ||
| ChangeInPayablesAndAccruedExpense | 4.84M | 5.22M | 1.96M | 2.42M |
| ChangeInAccruedExpense | 8.00M | 2.94M | -638.00K | 1.80M |
| ChangeInPayable | -3.16M | 2.28M | 2.60M | 623.00K |
| ChangeInAccountPayable | -3.16M | 2.28M | 2.60M | 623.00K |
| ChangeInPrepaidAssets | -596.00K | -5.83M | 744.00K | -1.56M |
| ChangeInInventory | 0.00 | 0.00 | ||
| ChangeInReceivables | -200.00K | 31.00K | 485.00K | -277.00K |
| ChangesInAccountReceivables | 0.00 | 31.00K | 485.00K | -277.00K |
| OtherNonCashItems | -4.37M | -4.06M | 74.00K | 9.33M |
| StockBasedCompensation | 7.34M | 5.86M | 6.05M | 7.71M |
| DepreciationAmortizationDepletion | 26.00K | 62.00K | 118.00K | 72.00K |
| DepreciationAndAmortization | 26.00K | 62.00K | 118.00K | 72.00K |
| AmortizationCashFlow | 0.00 | 0.00 | ||
| AmortizationOfIntangibles | 0.00 | 0.00 | ||
| Depreciation | 26.00K | 62.00K | 118.00K | 72.00K |
| OperatingGainsLosses | 19.15M | |||
| GainLossOnInvestmentSecurities | 19.15M | |||
| NetIncomeFromContinuingOperations | -130.64M | -87.37M | -73.81M | -71.20M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VSTM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|